| Heart disease and stroke statistics—2016 update: a report from the American Heart Association D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman, ... circulation 133 (4), e38-e360, 2016 | 65395* | 2016 |
| Dabigatran versus warfarin in patients with atrial fibrillation SJ Connolly, MD Ezekowitz, S Yusuf, J Eikelboom, J Oldgren, A Parekh, ... New England Journal of Medicine 361 (12), 1139-1151, 2009 | 13649 | 2009 |
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators New England Journal of Medicine 345 (7), 494-502, 2001 | 8586 | 2001 |
| 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation developed … Authors/Task Force Members, AJ Camm, GYH Lip, R De Caterina, ... European heart journal 33 (21), 2719-2747, 2012 | 6440 | 2012 |
| Edoxaban versus warfarin in patients with atrial fibrillation RP Giugliano, CT Ruff, E Braunwald, SA Murphy, SD Wiviott, JL Halperin, ... New England Journal of Medicine 369 (22), 2093-2104, 2013 | 5586 | 2013 |
| Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium R Mehran, SV Rao, DL Bhatt, CM Gibson, A Caixeta, J Eikelboom, S Kaul, ... Circulation 123 (23), 2736-2747, 2011 | 4050 | 2011 |
| Apixaban in patients with atrial fibrillation SJ Connolly, J Eikelboom, C Joyner, HC Diener, R Hart, S Golitsyn, ... New England Journal of Medicine 364 (9), 806-817, 2011 | 3259 | 2011 |
| COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review B Bikdeli, MV Madhavan, D Jimenez, T Chuich, I Dreyfus, E Driggin, ... Journal of the American college of cardiology 75 (23), 2950-2973, 2020 | 3222 | 2020 |
| Rivaroxaban with or without aspirin in stable cardiovascular disease JW Eikelboom, SJ Connolly, J Bosch, GR Dagenais, RG Hart, ... New England Journal of Medicine 377 (14), 1319-1330, 2017 | 2219 | 2017 |
| Adverse impact of bleeding on prognosis in patients with acute coronary syndromes JW Eikelboom, SR Mehta, SS Anand, C Xie, KAA Fox, S Yusuf Circulation 114 (8), 774-782, 2006 | 1997* | 2006 |
| Idarucizumab for dabigatran reversal CV Pollack Jr, PA Reilly, J Eikelboom, S Glund, P Verhamme, ... New England Journal of Medicine 373 (6), 511-520, 2015 | 1979 | 2015 |
| Dabigatran versus warfarin in patients with mechanical heart valves JW Eikelboom, SJ Connolly, M Brueckmann, CB Granger, AP Kappetein, ... New England Journal of Medicine 369 (13), 1206-1214, 2013 | 1637 | 2013 |
| Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events JW Eikelboom, J Hirsh, JI Weitz, M Johnston, Q Yi, S Yusuf Circulation 105 (14), 1650-1655, 2002 | 1627 | 2002 |
| Homocysteine and vascular disease GJ Hankey, JW Eikelboom The lancet 354 (9176), 407-413, 1999 | 1564 | 1999 |
| Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term … JW Eikelboom, L Wallentin, SJ Connolly, M Ezekowitz, JS Healey, ... Circulation 123 (21), 2363-2372, 2011 | 1498 | 2011 |
| Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta‐analysis SG Chu, RC Becker, PB Berger, DL Bhatt, JW Eikelboom, B Konkle, ... Journal of Thrombosis and Haemostasis 8 (1), 148-156, 2009 | 1367 | 2009 |
| Homocyst (e) ine and cardiovascular disease: a critical review of the epidemiologic evidence JW Eikelboom, E Lonn, J Genest Jr, G Hankey, S Yusuf Annals of internal medicine 131 (5), 363-375, 1999 | 1356 | 1999 |
| Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis … L Wallentin, S Yusuf, MD Ezekowitz, M Alings, M Flather, MG Franzosi, ... The Lancet 376 (9745), 975-983, 2010 | 1283 | 2010 |
| Idarucizumab for dabigatran reversal—full cohort analysis CV Pollack Jr, PA Reilly, J Van Ryn, JW Eikelboom, S Glund, ... New England Journal of Medicine 377 (5), 431-441, 2017 | 1125 | 2017 |
| Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes … SR Mehta, JF Tanguay, JW Eikelboom, SS Jolly, CD Joyner, CB Granger, ... The Lancet 376 (9748), 1233-1243, 2010 | 1098 | 2010 |
Graeme J. HankeyWInthrop Professor of Neurology, The University of Western Australia; Neurologist, Sir CharlesVerified email at uwa.edu.au
